News
A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. Rebecca Ann Redman , Paula Raffin ...
Multiple secondary endpoints have been incorporated to assess the effects of PFK-158 on peripheral blood mononuclear cell F2,6BP activity, and on glucose uptake using FDG-PET imaging. This trial is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback